Phospholipase A2 expression in tumours: A target for therapeutic intervention?

Drug Discovery Today

Volumn 8, Issue 15, 2003, Pages 710-716

  Laye, Jonathan P ^a   Gill, Jason H ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

Arachidonic acid; Cancer biology; CPLA2; Drug Discovery; Molecular target; Pharmaceutical Science; Phospholipase A2; SPLA2

Indexed keywords

PHOSPHOLIPASE A2; CALCIUM; PHOSPHOLIPASE A;

CANCER CHEMOTHERAPY; DRUG DELIVERY SYSTEM; DRUG TARGETING; ENZYME RELEASE; GENE ACTIVITY; HOUSEKEEPING GENE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; ONCOGENE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TUMOR SUPPRESSOR GENE; ANIMAL; BIOSYNTHESIS; CYTOSOL; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METHODOLOGY; NEOPLASM; PHYSIOLOGY; SECRETION;

ANIMALS; CALCIUM; CYTOSOL; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; PHOSPHOLIPASES A;

EID: 0043123204     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02754-5     Document Type: Review

References (60)

1. Murakami M., Kudo I. Phospholipase A2. J. Biochem. (Tokyo). 131:2002;285-292.
2. Harris S.G., et al. Prostaglandins as modulators of immunity. Trends Immunol. 23:2002;144-150.
3. Pai R., et al. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med. 8:2002;289-293.
4. Marks F., et al. A causal relationship between unscheduled eicosanoid signaling and tumour development: Cancer chemoprevention by inhibitors of arachidonic acid metabolism. Toxicology. 153:2000;11-26.
5. Tapiero H., et al. Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies. Biomed. Pharmacother. 56:2002;215-222.
6. Capper E.A., Marshall L.A. Mammalian phospholipases A(2): mediators of inflammation, proliferation and apoptosis. Prog. Lipid Res. 40:2001;167-197.
7. Fuentes L., et al. Biological effects of group IIA secreted phosholipase A(2). FEBS Lett. 531:2002;7-11.
8. Nevalainen T.J., et al. Roles of secretory phospholipases A(2) in inflammatory diseases and trauma. Biochim. Biophys. Acta. 1488:2000;83-90.
9. Pfeilschifter J., et al. Cytokine regulation of group II phospholipase A2 expression in glomerular mesangial cells. Eur. J. Clin. Pharmacol. 44:1993;S7-S9.
10. Crowl R.M., et al. Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. J. Biol. Chem. 266:1991;2647-2651.
11. Andreani M., et al. Transcriptional regulation of inflammatory secreted phospholipases A(2). Biochim. Biophys. Acta. 1488:2000;149-158.
12. Nakano T., Arita H. Enhanced expression of group II phospholipase A2 gene in the tissues of endotoxin shock rats and its suppression by glucocorticoid. FEBS Lett. 273:1990;23-26.
13. Laine V.J., et al. Neutrophil response of transgenic mice expressing human group IIA phospholipase A2 in bacterial infections. Scand. J. Immunol. 52:2000;362-368.
14. Tietge U.J., et al. Overexpression of secretory phospholipase A(2) causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I. J. Biol. Chem. 275:2000;10077-10084.
15. Jiang J., et al. Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma. Am. J. Pathol. 160:2002;667-671.
16. Graff J.R., et al. Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade. Clin. Cancer Res. 7:2001;3857-3861.
17. Kennedy B.P., et al. Overexpression of the nonpancreatic secretory group II PLA2 messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients. Cancer Res. 58:1998;500-503.
18. Murata K., et al. Expression of group-II phospholipase A2 in malignant and non-malignant human gastric mucosa. Br. J. Cancer. 68:1993;103-111.
19. Leung S.Y., et al. Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. Proc. Natl. Acad. Sci. U. S. A. 99:2002;16203-16208.
20. Kiyohara H., et al. Immunohistochemical localization of group II phospholipase A2 in human pancreatic carcinomas. Int. J. Pancreatol. 13:1993;49-57.
21. Edhemovic I., et al. Immunohistochemical localization of group II phospholipase A2 in the tumours and mucosa of the colon and rectum. Eur. J. Surg. Oncol. 27:2001;545-548.
22. Wendum D., et al. COX-2, Inflammatory Secreted PLA2, and Cytoplasmic PLA2 Protein Expression in Small Bowel Adenocarcinomas Compared with Colorectal Adenocarcinomas. Mod. Pathol. 16:2003;130-136.
23. Praml C., et al. Secretory type II phospholipase A2 (PLA2G2A) expression status in colorectal carcinoma derived cell lines and in normal colonic mucosa. Oncogene. 17:1998;2009-2012.
24. Cormier R.T., et al. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nat. Genet. 17:1997;88-91.
25. MacPhee M., et al. The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell. 81:1995;957-966.
26. Kawamata N., et al. Molecular analysis of the secretory phospholipase A2 gene, a candidate of Mom1 gene, in neuroblastomas. Cancer Lett. 111:1997;71-75.
27. Riggins G.J., et al. Absence of secretory phospholipase A2 gene alterations in human colorectal cancer. Cancer Res. 55:1995;5184-5186.
28. Tomlinson I.P., et al. Variants at the secretory phospholipase A2 (PLA2G2A) locus: analysis of associations with familial adenomatous polyposis and sporadic colorectal tumours. Ann. Hum. Genet. 60:1996;369-376.
29. Haluska F.G., et al. Lack of phospholipase A2 mutations in neuroblastoma, melanoma and colon-cancer cell lines. Int. J. Cancer. 72:1997;337-339.
30. Longo W.E., et al. The effect of phospholipase A2 inhibitors on proliferation and apoptosis of murine intestinal cells. J. Surg. Res. 84:1999;51-56.
31. Taketo M.M., Sonoshita M. Phospolipase A2 and apoptosis. Biochim. Biophys. Acta. 1585:2002;72-76.
32. Chen W.M., et al. Control of capillary formation by membrane-anchored extracellular inhibitor of phospholipase A(2). FEBS Lett. 522:2002;113-118.
33. Silverman K.A., et al. Exclusion of Madh2, Madh4, and Madh7 as candidates for the modifier of Min 2 (Mom2) locus. Mamm. Genome. 14:2003;119-129.
34. Silverman K.A., et al. Identification of the modifier of Min 2 (Mom2) locus, a new mutation that influences Apc-induced intestinal neoplasia. Genome Res. 12:2002;88-97.
35. Yedgar S., et al. Inhibition of phospholipase A(2) as a therapeutic target. Biochim. Biophys. Acta. 1488:2000;182-187.
36. Miele L. New weapons against inflammation: dual inhibitors of phospholipase A2 and transglutaminase. J. Clin. Invest. 111:2003;19-21.
37. Balsinde J., et al. Regulation and inhibition of phospholipase A2. Annu. Rev. Pharmacol. Toxicol. 39:1999;175-189.
38. Davidsen J., et al. Secreted phospholipase A(2) as a new enzymatic trigger mechanism for localised liposomal drug release and absorption in diseased tissue. Biochim. Biophys. Acta. 1609:2003;95-101.
39. Attiga F.A., et al. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res. 60:2000;4629-4637.
40. Zerouga M., et al. Synthesis of a novel phosphatidylcholine conjugated to docosahexaenoic acid and methotrexate that inhibits cell proliferation. Anticancer Drugs. 13:2002;301-311.
41. Larsson P.K., et al. Multiple splice variants of the human calcium-independent phospholipase A2 and their effect on enzyme activity. J. Biol. Chem. 273:1998;207-214.
42. 2+-independent phospholipase A2 blocks phospholipid fatty acid remodeling in murine P388D1 macrophages. J. Biol. Chem. 272:1997;29317-29321.
43. Winstead M.V., et al. Calcium-independent phospholipase A(2): structure and function. Biochim. Biophys. Acta. 1488:2000;28-39.
44. Murakami M., et al. The functions of five distinct mammalian phospholipase A2S in regulating arachidonic acid release. Type IIa and type V secretory phospholipase A2S are functionally redundant and act in concert with cytosolic phospholipase A2. J. Biol. Chem. 273:1998;14411-14423.
45. 2+-independent phospholipase A2 augments spontaneous fatty acid release. J. Biol. Chem. 275:2000;18248-18258.
46. Pickard R.T., et al. Molecular cloning of two new human paralogs of 85-kDa cytosolic phospholipase A2. J. Biol. Chem. 274:1999;8823-8831.
47. Hirabayashi T., Shimizu T. Localization and regulation of cytosolic phospholipase A(2). Biochim. Biophys. Acta. 1488:2000;124-138.
48. Clark J.D., et al. A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP. Cell. 65:1991;1043-1051.
49. Lin L.L., et al. cPLA2 is phosphorylated and activated by MAP kinase. Cell. 72:1993;269-278.
50. Hefner Y., et al. Serine 727 phosphorylation and activation of cytosolic phospholipase A2 by MNK1-related protein kinases. J. Biol. Chem. 275:2000;37542-37551.
51. Diez E., et al. Fatty acid and phospholipid selectivity of different phospholipase A2 enzymes studied by using a mammalian membrane as substrate. Biochem. J. 301:1994;721-726.
52. Dimberg J., et al. Gene expression of cyclooxygenase-2, group II and cytosolic phospholipase A2 in human colorectal cancer. Anticancer Res. 18:1998;3283-3287.
53. Osterstrom A., et al. Expression of cytosolic and group X secretory phospholipase A(2) genes in human colorectal adenocarcinomas. Cancer Lett. 182:2002;175-182.
54. Heasley L.E., et al. Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer. J. Biol. Chem. 272:1997;14501-14504.
55. Xu X.C. COX-2 inhibitors in cancer treatment and prevention, a recent development. Anticancer Drugs. 13:2002;127-137.
56. Blaine S.A., et al. Induction of cPLA2 in lung epithelial cells and non-small cell lung cancer is mediated by Sp1 and c-Jun. J. Biol. Chem. 276:2001;42737-42743.
57. Hong K.H., et al. Deletion of cytosolic phospholipase A(2) suppresses Apc(Min)-induced tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 98:2001;3935-3939.
58. Takaku K., et al. Suppression of intestinal polyposis in Apc(delta 716) knockout mice by an additional mutation in the cytosolic phospholipase A(2) gene. J. Biol. Chem. 275:2000;34013-34016.
59. Dong M., et al. Inverse association between phospholipase A2 and COX-2 expression during mouse colon tumorigenesis. Carcinogenesis. 24:2003;307-315.
60. Balsinde J., et al. Functional coupling between secretory phospholipase A2 and cyclooxygenase-2 and its regulation by cytosolic group IV phospholipase A2. Proc. Natl. Acad. Sci. U. S. A. 95:1998;7951-7956.